Moderators: Heidi Gray, MD & Roisin O’Cearbhail, MD

• A Randomized Phase 3 Trial of Intraperitoneal Versus Intravenous Carboplatin with Dose-Dense Weekly Paclitaxel in Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (a GOTIC-001/JGOG-3019/GCIG, iPocc Trial) – Speaker: K. Fujiwara
• Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study – Speaker: U. Matulonis
• Distillation – Speaker: D. Armstrong
• Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Newly Diagnosed Advanced Ovarian Cancer Using an Individualized Starting Dose (PRIME Study): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial – Speaker: N. Li
• Predictive Value of the Leuven HRD Test Compared with Myriad myChoice PLUS on 468 Ovarian Cancer Samples from the PAOLA-1/ENGOT-ov25 Trial – Speaker: L. Loverix
• The Genomic Landscape of Low-Grade Serous Ovarian/Peritoneal Carcinoma (LGSOC) and its Impact on Clinical Outcome – Speaker: D. Gershenson
• Genomic Alterations, Molecularly Targeted Therapy and Race: Real World Data from the Endometrial Cancer Molecularly Targeted Therapy Consortium – Speaker: A. Alvarez-Secord
• Distillation – Speaker: B. Norquist
• SIENDO/ENGOT-EN5/GOG-3055: A Randomized Phase 3 trial of Maintenance Selinexor Versus Placebo after Combination Platinum-Based Chemotherapy in Advanced or Recurrent Endometrial Cancer – Speaker: I. Vergote
• Open vs. Minimally Invasive Radical Hysterectomy in Early Cervical Cancer: LACC Trial Final Analysis – Speaker: R. Ramirez
• Distillation – Speaker: K. Bixel

This session was recorded live at the 2022 AM on Women’s Cancer in March 2022.